<DOC>
	<DOC>NCT01163851</DOC>
	<brief_summary>The primary objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of a single dose of PF-04950615 (RN316) in volunteers on stable doses of atorvastatin. PF-04950615 (RN316) is an investigational drug that is currently being studies as a cholesterol lowering therapy.</brief_summary>
	<brief_title>Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>On stable doses of atorvastatin (40 mg daily) for 45 days prior to Day 1. BMI 18.5 to 40 kg/m2 inclusive, and body weight equal or lower than 150 kg. History of a cardiovascular event (e.g., MI ) during the past year. Poorly controlled Type 1 or Type 2 Diabetes mellitus (definition: uncontrolled diabetes is defined as HBIAc &gt;9%). Poorly controlled hypertension (uncontrolled hypertension is defined as a systolic blood pressure greater than 140 mm Hg or a diastolic blood pressure greater than 90 mm Hg, even with treatment). Subjects who have hypertension and are controlled on stable dosages of antihypertensive medications can be included.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>LDL</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>High Cholesterol</keyword>
	<keyword>PF-04950615</keyword>
	<keyword>RN316</keyword>
</DOC>